A Phase 3, Randomized, Controlled, Multicenter, Open-Label Study to Compare Tivozanib in Combination with Nivolumab to Tivozanib Monotherapy in Subjects with Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy

Grants and Contracts Details

StatusActive
Effective start/end date5/25/22 → 10/30/24

Funding

  • AVEO Pharmaceuticals Incorporated: $49,432.00